The SUREtechnology Platform, developed and owned by Selexis, SA, is an underlying technology of some of Ligand’s royalty-bearing assets and is based on novel DNA-based elements that control the dynamic organization of chromatin within mammalian cells and allow for higher and more stable expression of recombinant proteins. This improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs.
Key significant advantages over traditional approaches include:
Speed
High Yield
Stability
Learn more at SUREtechnology Platform overview
